收费全文 | 2535篇 |
免费 | 207篇 |
国内免费 | 11篇 |
耳鼻咽喉 | 5篇 |
儿科学 | 146篇 |
妇产科学 | 36篇 |
基础医学 | 351篇 |
口腔科学 | 31篇 |
临床医学 | 188篇 |
内科学 | 514篇 |
皮肤病学 | 44篇 |
神经病学 | 296篇 |
特种医学 | 212篇 |
外科学 | 294篇 |
综合类 | 29篇 |
预防医学 | 164篇 |
眼科学 | 103篇 |
药学 | 135篇 |
肿瘤学 | 205篇 |
2021年 | 26篇 |
2019年 | 45篇 |
2018年 | 33篇 |
2017年 | 24篇 |
2016年 | 32篇 |
2015年 | 33篇 |
2014年 | 56篇 |
2013年 | 80篇 |
2012年 | 100篇 |
2011年 | 99篇 |
2010年 | 73篇 |
2009年 | 62篇 |
2008年 | 108篇 |
2007年 | 104篇 |
2006年 | 112篇 |
2005年 | 105篇 |
2004年 | 104篇 |
2003年 | 80篇 |
2002年 | 99篇 |
2001年 | 79篇 |
2000年 | 103篇 |
1999年 | 77篇 |
1998年 | 53篇 |
1997年 | 44篇 |
1996年 | 28篇 |
1995年 | 29篇 |
1994年 | 24篇 |
1993年 | 29篇 |
1992年 | 59篇 |
1991年 | 57篇 |
1990年 | 61篇 |
1989年 | 73篇 |
1988年 | 59篇 |
1987年 | 39篇 |
1986年 | 48篇 |
1985年 | 45篇 |
1984年 | 40篇 |
1983年 | 31篇 |
1982年 | 22篇 |
1981年 | 23篇 |
1980年 | 20篇 |
1979年 | 22篇 |
1978年 | 17篇 |
1977年 | 19篇 |
1976年 | 16篇 |
1975年 | 16篇 |
1974年 | 18篇 |
1973年 | 19篇 |
1969年 | 20篇 |
1968年 | 18篇 |
Background and aim
Cholangiocyte proliferation is coordinately regulated by a number of gastrointestinal hormones/peptides, some of which display stimulatory effects and some have inhibitory actions on cholangiocyte proliferation. Enhanced biliary proliferation [for example after bile duct ligation (BDL) and partial hepatectomy] is associated with increased expression of secretin receptor (SR), cystic fibrosis transmembrane conductance regulator (CFTR) and Cl–/HCO3– anion exchanger 2 and secretin-stimulated ductal secretion, whereas loss/damage of bile ducts [for example after acute carbon tetrachloride (CCl4) administration] is associated with reduced secretin-stimulated ductal secretory activity. There is growing information regarding the role of gastrointestinal hormones the regulation of biliary growth. For example, while gastrin, somatostatin and serotonin inhibit bile duct hyperplasia of cholestatic rats by downregulation of cAMP signaling, secretin has been shown to stimulate the proliferation of normal mice by activation of cyclic adenosine 3'',5''-monophosphate (cAMP)-dependent signaling. However, no information exists regarding the stimulatory effects of secretin on biliary proliferation of normal rats. Thus, we evaluated the in vivo and in vitro effect of secretin on biliary proliferation, the expression of markers key of ductal secretion and secretin-stimulated ductal secretion.Methods
Normal male rats were treated with saline or secretin (2.5 nmoles/kg BW/day by osmotic minipumps for one week). We evaluated: (I) intrahepatic bile duct mass (IBDM) in liver sections and PCNA expression in purified cholangiocytes; (II) SR and CFTR mRNA expression and secretin-stimulated cAMP levels in purified cholangiocytes; and (III) secretin-stimulated bile and bicarbonate secretion in bile fistula rats. In vitro, normal rat intrahepatic cholangiocyte lines (NRIC) were treated with BSA (basal) or secretin (100 nM) for 24 to 72 hours in the absence/presence of a PKA or a MEK inhibitor before evaluating proliferation by MTS assays.Results
Prolonged administration of secretin to normal rats increased IBDM and PCNA expression in purified cholangiocytes compared to saline-treated normal rats. Also, secretin increased the expression of proteins (SR and CFTR) that are key in the regulating ductal secretion and enhanced secretin-stimulated cAMP levels and bile and bicarbonate secretion. In vitro, secretin increased the proliferation of NRIC, increase that was prevented by PKA and MAPK inhibitors.Conclusions
We have demonstrated that secretin stimulates both in vivo and in vitro biliary proliferation and secretin-stimulated ductal secretory activity in normal rats. We suggest that the stimulatory effect of secretin on biliary proliferation and secretion may be important for preventing biliary dysfunction during ductopenic disorders. 相似文献Background and aims
Reduction of biliary serotonin N-acetyltransferase (AANAT) expression and melatonin administration/secretion in cholangiocytes increases biliary proliferation and the expression of SR, CFTR and Cl–/HCO3– AE2. The balance between biliary proliferation/damage is regulated by several autocrine neuroendocrine factors including vascular endothelial growth factor-A/C (VEGF-A/C). VEGFs are secreted by several epithelia, where they modulate cell growth by autocrine and paracrine mechanisms. No data exists regarding the effect of AANAT modulation on the expressions of VEGFs by cholangiocytes.Methods
In this study, we evaluated the effect of local modulation of biliary AANAT expression on the cholangiocytes synthesis of VEGF-A/C.Results
The decrease in AANAT expression and subsequent lower melatonin secretion by cholangiocytes was associated with increased expression of VEGF-A/C. Overexpression of AANAT in cholangiocyte lines decreased the expression of VEGF-A/C.Conclusions
Modulation of melatonin synthesis may affect the expression of VEGF-A/C by cholangiocytes and may modulate the hepatic microvascularization through the regulation of VEGF-A/C expression regulating biliary functions. 相似文献We were intrigued by reports of the inhibition of phospholipase A2 (PLA2) by indomethacin. In order to increase the potency of the indomethacin system as an inhibitor of PLA2, it was decided to make more lipophilic analogs. Indeed, covalent attachment of a quinoline ring to the methoxy substituent of indomethacin affords WAY-122,220 which is almost an order of magnitude more potent than indomethacin in inhibiting human synovial fluid PLA2 (IC50=15 and 145 μM, respectively). TheN−p-chloro-benzyl analog of this compound, WAY-121,520, was an even more potent inhibitor of PLA2 (IC50=4 μM). Structural analyses and molecular modeling suggest that these compounds may inhibit PLA2 by mimicking arachidonic acid. WAY-121,520 is also a potent leukotriene biosynthesis inhibitor both in the rat PMN and mouse macrophage assays (IC50=10 and 4 nM, respectively), possibly acting via a 5-LO (5-lipoxygenase) translocation inhibition mechanism. The multiple actions of WAY-121,520 may contribute to its favorable anti-inflammatory profile.
相似文献